{
    "clinical_study": {
        "@rank": "132914", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Apixaban", 
                "arm_group_type": "Experimental", 
                "description": "Single dose Apixaban  5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe"
            }, 
            {
                "arm_group_label": "Arm B: Apixaban", 
                "arm_group_type": "Experimental", 
                "description": "Single dose Apixaban  5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT"
            }, 
            {
                "arm_group_label": "Arm C: Apixaban", 
                "arm_group_type": "Experimental", 
                "description": "Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the bioavailability of Apixaban solution administered\n      through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to\n      Apixaban solution administered orally in healthy subjects"
        }, 
        "brief_title": "Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects", 
        "completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Healthy subjects as determined by no clinically significant deviation from normal in\n        medical history, physical examination, ECGs, and clinical laboratory determinations\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Any history or evidence of abnormal bleeding or coagulation disorders, intracranial\n             hemorrhage, or  abnormal bleeding (including heavy menstrual bleeding that has\n             resulted in anemia within the past 1 year) or coagulation disorders in a first degree\n             relative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034578", 
            "org_study_id": "CV185-091"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A: Apixaban", 
                "Arm B: Apixaban", 
                "Arm C: Apixaban"
            ], 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "BMS-562247"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 10, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "Parexel Baltimore Early Phase Clinical Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Study of Apixaban Oral Solution Bioavailability When Administered Through a Nasogastric Tube in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban administered orally in healthy subjects", 
            "safety_issue": "No", 
            "time_frame": "Up to Day 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034578"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety assessed by incidence of adverse events, results of vital sign measurements, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 12"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "48 time points up to Day 12"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "48 time points up to Day 12"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to the time of last quantifiable plasma concentration [AUC(0-T)] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "48 time points up to Day 12"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "48 time points up to Day 12"
            }, 
            {
                "measure": "Plasma elimination half-life (T-HALF) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "48 time points up to Day 12"
            }, 
            {
                "measure": "Relative bioavailability as calculated by ratio of AUC(INF) [Frel] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "48 time points up to Day 12"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}